Anovo Recognized for Creation of “End-to-End” Service Model that Benefits Both Patients and Manufacturers
September 5, 2023
Anovo is excited to announce that we have been featured in an article for USA Today, which details our unique ability to react to both business and patient needs.
In this piece, our co-founder and CEO, Jon Peters, speaks to the vision of creating a specialty pharmacy built to service small patient populations with diverse needs. “What we saw going on in the market was industry consolidation,” he said in regard to creating end-to-end services for both manufacturers of rare disease therapies and the patients who need them. “All the independent specialty pharmacies were being acquired by larger payer entities and distributors, which created a void in the market for a single-source provider focused on rare diseases.”
Anovo creates an unmatched patient experience by supplying a full continuum of people who need to be involved in a patient’s treatment – such as intake specialists, reimbursement specialists, billing specialists, patient assistance program specialists, pharmacy technicians, pharmacists and nurses – for each product they service. By building a system designed to take a product from the manufacturer all the way to the consumer, our model is more cost-effective for manufacturers while remaining dedicated to bettering the experience of our patients.
Read the full article for details about Anovo’s patient-centric approach and the value our exclusive model affords to manufacturers of orphan drugs.
Related Posts
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 30, 2025
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
